209 related articles for article (PubMed ID: 27664326)
21. Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome.
Pical-Izard C; Crocchiolo R; Granjeaud S; Kochbati E; Just-Landi S; Chabannon C; Frassati C; Picard C; Blaise D; Olive D; Fauriat C
Biol Blood Marrow Transplant; 2015 Mar; 21(3):429-39. PubMed ID: 25579888
[TBL] [Abstract][Full Text] [Related]
22. Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group.
Itonaga H; Taguchi J; Fukushima T; Tsushima H; Sato S; Ando K; Sawayama Y; Matsuo E; Yamasaki R; Onimaru Y; Imanishi D; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Honda S; Miyazaki Y
Biol Blood Marrow Transplant; 2013 Apr; 19(4):607-15. PubMed ID: 23333533
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
24. Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children.
Bartelink IH; Belitser SV; Knibbe CA; Danhof M; de Pagter AJ; Egberts TC; Boelens JJ
Biol Blood Marrow Transplant; 2013 Feb; 19(2):305-13. PubMed ID: 23092812
[TBL] [Abstract][Full Text] [Related]
25. Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation.
Servais S; Lengline E; Porcher R; Carmagnat M; Peffault de Latour R; Robin M; Sicre de Fontebrune F; Clave E; Maki G; Granier C; Xhaard A; Dhedin N; Molina JM; Toubert A; Moins-Teisserenc H; Socie G
Biol Blood Marrow Transplant; 2014 Apr; 20(4):507-17. PubMed ID: 24406505
[TBL] [Abstract][Full Text] [Related]
26. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
[TBL] [Abstract][Full Text] [Related]
27. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord.
Nguyen S; Achour A; Souchet L; Vigouroux S; Chevallier P; Furst S; Sirvent A; Bay JO; Socié G; Ceballos P; Huynh A; Cornillon J; Francois S; Legrand F; Yakoub-Agha I; Michel G; Maillard N; Margueritte G; Maury S; Uzunov M; Bulabois CE; Michallet M; Clement L; Dauriac C; Bilger K; Lejeune J; Béziat V; Rocha V; Rio B; Chevret S; Vieillard V
Bone Marrow Transplant; 2017 Oct; 52(10):1428-1435. PubMed ID: 28650455
[TBL] [Abstract][Full Text] [Related]
29. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
[TBL] [Abstract][Full Text] [Related]
30. Status of Natural Killer Cell Recovery in Day 21 Bone Marrow after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome.
Hattori N; Saito B; Sasaki Y; Shimada S; Murai S; Abe M; Baba Y; Watanuki M; Fujiwara S; Kawaguchi Y; Arai N; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Harada H; Nakamaki T
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1841-1847. PubMed ID: 29753837
[TBL] [Abstract][Full Text] [Related]
31. Delayed NK Cell Reconstitution and Reduced NK Activity Increased the Risks of CMV Disease in Allogeneic-Hematopoietic Stem Cell Transplantation.
Park KH; Ryu JH; Bae H; Yun S; Jang JH; Han K; Cho BS; Kim HJ; Lee H; Oh EJ
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455959
[TBL] [Abstract][Full Text] [Related]
32. Impact of Cytomegalovirus Reactivation and Natural Killer Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Analysis.
Ando T; Suzuki T; Ishiyama Y; Koyama S; Tachibana T; Tanaka M; Kanamori H; Nakajima H
Biol Blood Marrow Transplant; 2020 Jan; 26(1):171-177. PubMed ID: 31563574
[TBL] [Abstract][Full Text] [Related]
33. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
34. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.
Bejanyan N; Brunstein CG; Cao Q; Lazaryan A; Luo X; Curtsinger J; Mehta RS; Warlick E; Cooley SA; Blazar BR; Miller JS; Weisdorf D; Wagner JE; Verneris MR
Blood Adv; 2018 Apr; 2(8):909-922. PubMed ID: 29678809
[TBL] [Abstract][Full Text] [Related]
35. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
36. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
Ringdén O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M;
Br J Haematol; 2017 Feb; 176(3):431-439. PubMed ID: 27879990
[TBL] [Abstract][Full Text] [Related]
37. Donor Killer Immunoglobulin-Like Receptor Profile Bx1 Imparts a Negative Effect and Centromeric B-Specific Gene Motifs Render a Positive Effect on Standard-Risk Acute Myeloid Leukemia/Myelodysplastic Syndrome Patient Survival after Unrelated Donor Hematopoietic Stem Cell Transplantation.
Bao X; Wang M; Zhou H; Zhang H; Wu X; Yuan X; Li Y; Wu D; He J
Biol Blood Marrow Transplant; 2016 Feb; 22(2):232-239. PubMed ID: 26371372
[TBL] [Abstract][Full Text] [Related]
38. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
[TBL] [Abstract][Full Text] [Related]
39. Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes.
Mo XD; Kong J; Zhao T; Xu LP; Zhang XH; Liu DH; Wang Y; Chen H; Yan CH; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2023-8. PubMed ID: 25196855
[TBL] [Abstract][Full Text] [Related]
40. Detrimental effect of natural killer cell alloreactivity in T-replete hematopoietic cell transplantation (HCT) for leukemia patients.
Sun JY; Dagis A; Gaidulis L; Miller MM; Rodriguez R; Parker P; Nademanee A; Falk P; Rosenthal J; Forman SJ; Senitzer D
Biol Blood Marrow Transplant; 2007 Feb; 13(2):197-205. PubMed ID: 17241925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
